Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Capital Expenditures (2021 - 2025)

Historic Capital Expenditures for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $1.7 million.

  • Krystal Biotech's Capital Expenditures rose 71739.13% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 1144.86%. This contributed to the annual value of $8.5 million for FY2024, which is 2798.54% down from last year.
  • As of Q3 2025, Krystal Biotech's Capital Expenditures stood at $1.7 million, which was up 71739.13% from $1.9 million recorded in Q2 2025.
  • Krystal Biotech's Capital Expenditures' 5-year high stood at $40.9 million during Q4 2021, with a 5-year trough of -$867000.0 in Q2 2023.
  • In the last 5 years, Krystal Biotech's Capital Expenditures had a median value of $5.2 million in 2022 and averaged $8.0 million.
  • In the last 5 years, Krystal Biotech's Capital Expenditures tumbled by 36285.71% in 2024 and then soared by 160000.0% in 2025.
  • Over the past 5 years, Krystal Biotech's Capital Expenditures (Quarter) stood at $40.9 million in 2021, then tumbled by 87.24% to $5.2 million in 2022, then plummeted by 86.66% to $696000.0 in 2023, then plummeted by 70.55% to $205000.0 in 2024, then skyrocketed by 731.22% to $1.7 million in 2025.
  • Its Capital Expenditures was $1.7 million in Q3 2025, compared to $1.9 million in Q2 2025 and $6.2 million in Q1 2025.